Centre Georges Francois Leclerc

Dijon, Bourgogne-Franche-Comté 21034

2 studies enrolling now · 7 studies all time

What they study most

Advanced Solid Tumors, Endometrial Cancer, Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Melanoma, Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma, NSCLC, Ovarian Cancer, Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Cancer

Studies at this site

• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — Recruiting now
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — Recruiting now
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery — Running, not enrolling
• A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers — Running, not enrolling
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma — Running, not enrolling
• Phase 3 Study to Treat Patients With Soft Tissue Sarcomas — Completed